Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple-dose study of M875T3 in healthy Japanese adult men
jRCT2071260092Phase 1Recruiting
- Sponsor
- Medisa Shinyaku
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apremilast, sponsored by Medisa Shinyaku. Primary endpoints: Safety, Tolerability and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
apremilast
Beyond the preview
Go deeper on jRCT2071260092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260092.